Medindia

X

Parisian Peel(R) Introduces Anti-Aging Suffusion System

Saturday, April 5, 2008 General News J E 4
Advertisement
GOLDEN, Colo., April 4, 2008 Aesthetic Technologiesannounced during the 28th Annual American Society for Laser Medicine andSurgery (ASLMS) Conference, in Kissimmee, Fla., the introduction of itsParisian Peel(R) Suffusion System. The breakthrough system is designed to helpphysicians and skin care professionals achieve better topical productpenetration than other systems currently on the market. Suffusion treatspeople with all skin types, offers zero downtime and exhibits proven results.

Suffusion's unique combination of ingredients in its topical formula,combined with its proven phonophoresis technique -- a method of electricallyassisted percutaneous delivery of macromolecules -- has shown very promisingresults in a just completed scientific study. Nationally recognizeddermatologist David J. Goldberg, M.D., of Skin Laser & Surgery Specialists ofN.Y. & N.J., will present a poster session at the ASLMS Conference (April 2-6)reading the study: "Evaluation of Histologic and Electron Microscopic Changesafter Novel Combined Microdermabrasion and Ultrasound Induced PhonophoresisTreatment of Human Skin."

"We have achieved extremely positive results with this technique," saidAlison Shaya, president of Aesthetic Technologies, explaining the studyresults.

The clinical study showed both an increase in collagen formation and highpatient satisfaction. All participants in the study reported a 25-percent orgreater improvement in hue/brightness of skin, and more than 85 percent of theparticipants reported a 25-percent or greater improvement in skin tone and a25-percent or greater improvement in skin dryness.

"Adding the Suffusion System to the service mix will open up exciting newopportunities for medically oriented skin care practices," Shaya said, "bothin terms of increased revenue and the ability to attract new patients."

The non-invasive, pain-free Suffusion System is the first of its kind inthe industry and represents a completely new method for achieving clinicallyvalidated dermal penetration down to the cellular level. The standardprocedure consists of a Parisian Peel immediately followed by dermal infusion,a five-minute process to drive the ReVisage(TM) solution deep down into theskin for a true and lasting effect.

The system combines the Parisian Peel Elite(TM) Ultrasound device,uniquely designed hand pieces and specially formulated ReVisage topicalsolution. When administered on the skin by a trained professional, thehydrating process promotes cellular renovation, enhances fibroblastic activityand increases collagen synthesis.

Infusion devices that don't use phonophoresis are incapable of dermalpenetration, Shaya said, while Suffusion accomplishes what dermal infusion wasmeant to do: achieve topical penetration at the cellular level to stimulatecollagen growth.

Shaya added that devices claiming to do both microdermabrasion andinfusion simultaneously end up doing neither very well. With this type ofsystem, the hydrating product only remains on the skin for a few secondsbefore it is removed. Parisian Peel research has found that the skin needstime to adequately absorb topical moisturizers.

More information on Parisian Peel Suffusion System is available at theParisian Peel ASLMS exhibit in booth 824 or http://www.parisianpeel.com.

About Aesthetic Technologies

Aesthetic Technologies is the manufacturer of Parisian Peel, the leadingand best-supported microdermabrasion equipment for the medical industry. Thecompany delivers the highest quality and most reliable equipment on the market-- evidenced by a significant installed customer base and numerous peerreviews and independent research -- and remains at the forefront of aestheticmedicine.

Through its unique "Profitability Promise"(http://www.profitabilitypromise.com), no other aesthetic device manufacturercan match Aesthetic Tec
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Idenix Pharmaceuticals to Present at the Canaccord...
S
Terumo Cardiovascular Systems Responds to Allegati...